BioCentury
ARTICLE | Clinical News

GSK begins Phase II of malaria vaccine candidate

October 27, 2017 9:27 PM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) began a Phase II trial of intramuscular RTS,S vaccine (Mosquirix, GSK257049) to vaccinate against malaria infection.

The open-label, U.S. trial will evaluate adult and pediatric formulations of the vaccine in 160 malaria-naïve healthy adult volunteers. Three months after vaccination, subjects will be challenged with a controlled human malaria infection at the Walter Reed Army Institute of Research. The primary endpoint of the trial is the proportion of subjects with Plasmodium falciparum parasitemia. Secondary endpoints include time to onset of P. falciparum parasitemia, antibody concentration and safety...